Microbiological profile of ozenoxacin

Autor: Jordi Vila, Ilonka Zsolt, Domingo Gargallo-Viola, María García-Castillo, Ian Morrissey, Yuly López, Rafael Cantón

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname

Aim: To explore the antibacterial spectrum of ozenoxacin and compare its in vitro activity with that of other antibacterial agents. Materials & methods: In 2010, 10,054 isolates were collected from 128 centers worldwide. Minimum inhibitory concentrat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73e9a0275ba8e68e99b4cba236090349
https://doi.org/10.2217/fmb-2019-0089

Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates

Autor: Ian Morrissey, Jordi Vila, María García-Castillo, Domingo Gargallo-Viola, Ilonka Zsolt, Marta Tato, Yuly López, Rafael Cantón

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname

Aim: To compare the in vitro activity of the anti-impetigo agent, ozenoxacin, and other antimicrobial agents against Gram-positive clinical isolates from skin and soft tissue infections. Materials & methods: Isolates were collected in two studies: 10

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be8d281625d5163613e0da45cb399e11
https://doi.org/10.2217/fmb-2017-0289

A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes.

Autor: Iñigo Angulo-Barturen, María Belén Jiménez-Díaz, Teresa Mulet, Joaquín Rullas, Esperanza Herreros, Santiago Ferrer, Elena Jiménez, Alfonso Mendoza, Javier Regadera, Philip J Rosenthal, Ian Bathurst, David L Pompliano, Federico Gómez de las Heras, Domingo Gargallo-Viola

Publikováno v: PLoS ONE, Vol 3, Iss 5, p e2252 (2008)

To counter the global threat caused by Plasmodium falciparum malaria, new drugs and vaccines are urgently needed. However, there are no practical animal models because P. falciparum infects human erythrocytes almost exclusively. Here we describe a re

Externí odkaz: https://doaj.org/article/1fb989ce145c431cb4b570f7cac6ad62

Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs

Autor: Domingo Gargallo-Viola, Ilonka Zsolt, Teresa Blazquez, Malaika Awori, Luc Chouinard, Susan Y. Smith, Jorge Ignacio González Borroto, Cristina Tarragó

Publikováno v: Future microbiology. 13

Aim: Ozenoxacin is a nonfluorinated quinolone antibacterial approved for topical treatment of impetigo. Because quinolones have known chondrotoxic effects in juvenile animals, the potential toxicity of ozenoxacin was assessed in preclinical studies.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89814785adad7878d9734d8dd0d53445
https://pubmed.ncbi.nlm.nih.gov/29745239

Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis

Autor: Yuly López, Rafael Cantón, Domingo Gargallo-Viola, Ilonka Zsolt, Jordi Vila, Marta Tato

Publikováno v: Recercat. Dipósit de la Recerca de Catalunya
instname
PLoS ONE
Dipòsit Digital de la UB
Universidad de Barcelona
PLoS ONE, Vol 14, Iss 10, p e0223326 (2019)

Ozenoxacin (OZN) belongs to a new generation of non-fluorinated quinolones for the topical treatment of skin infections which has shown to be effective in the treatment of susceptible and resistant Gram-positive cocci. The mutant prevention concentra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::010563ee4484e3febd69130931bfe7d5
https://doi.org/10.1371/journal.pone.0223326